Increased aldehyde reductase expression mediates acquired radioresistance of laryngeal cancer cells via modulating p53

Cancer Biology and Therapy

Volumn 13, Issue 8, 2012, Pages 639-647

  Kim, Jae Sung ^a   Chang, Jong Wook ^b   Park, Jong Kuk ^a   Hwang, Sang Gu ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b MEDIPOST Co Ltd   (South Korea)

Author keywords

AKR1A1; Laryngeal cancer; p53; Radioresistance; Radiotherapy

Indexed keywords

ALDEHYDE REDUCTASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; SERINE; SMALL INTERFERING RNA; PROTEIN BINDING;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LARYNX CANCER; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEOMICS; RADIOSENSITIVITY; CELL DEATH; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; LARYNX TUMOR; METABOLISM; RADIATION DOSE; RADIATION RESPONSE;

ALDEHYDE REDUCTASE; CELL DEATH; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; LARYNGEAL NEOPLASMS; PROTEIN BINDING; PROTEIN STABILITY; RADIATION TOLERANCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862163055     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.8.20081     Document Type: Article

References (33)

1. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005; 104:1129-37; PMID:16080176; http://dx.doi.org/10.1002/cncr.21324.
2. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11:239-53; PMID:21430696; http://dx.doi.org/10.1038/nrc3007.
3. Milas L, Raju U, Liao Z, Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 2005; 32:78-81; PMID:16399438; http://dx.doi.org/10.1053/j.seminoncol.2005.04.028.
4. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008; 9:288-96; PMID:18308254; http://dx.doi.org/10.1016/S1470- 2045(08)70073-1.
5. Fei P, El-Deiry WS. p53 and radiation responses. Oncogene 2003; 22:5774-83; PMID:12947385; http://dx.doi.org/10.1038/sj.onc.1206677.
6. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003; 3:117-29; PMID:12563311; http://dx.doi.org/ 10.1038/nrc992.
7. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268:2764-72; PMID:11358490; http://dx.doi.org/10.1046/j.1432-327.2001.02225.x.
8. Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle 2007; 6:931-42; PMID:17457059; http://dx.doi.org/10.4161/cc.6.8.4180.
9. Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 2010; 18:619-29; PMID:21156285; http://dx.doi.org/10.1016/j.ccr.2010.10.034.
10. Jameel JK, Rao VS, Cawkwell L, Drew PJ. Radioresistance in carcinoma of the breast. Breast 2004; 13:452-60; PMID:15563851; http://dx.doi.org/10.1016/j. breast.2004.08.004.
11. Truman JP, Gueven N, Lavin M, Leibel S, Kolesnick R, Fuks Z, et al. Downregulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J Biol Chem 2005; 280:23262-72; PMID:15837784; http://dx.doi.org/10.1074/jbc.M503701200.
12. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem 2002; 277:47976-9; PMID:12388558; http://dx.doi.org/10.1074/jbc.C200538200.
13. Li DQ, Divijendra Natha Reddy S, Pakala SB, Wu X, Zhang Y, Rayala SK, et al. MTA1 coregulator regulates p53 stability and function. J Biol Chem 2009; 284:34545-52; PMID:19837670; http://dx.doi.org/10.1074/jbc.M109.056499.
14. Joo HM, Kim JY, Jeong JB, Seong KM, Nam SY, Yang KH, et al. Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2. Eur J Cell Biol 2011; 90:420-31; PMID:21333377; http://dx.doi.org/10. 1016/j.ejcb.2010.12.001.
15. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 2007; 47:263-92; PMID:16970545; http://dx.doi.org/10. 1146/annurev.pharmtox.47.120505.105337.
16. Ax W, Soldan M, Koch L, Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000; 59:293-300; PMID:10609558; http://dx.doi.org/10.1016/S0006-2952(99)00322-6.
17. Plebuch M, Soldan M, Hungerer C, Koch L, Maser E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett 2007; 255:49-56; PMID:17482758; http://dx.doi.org/10.1016/j.canlet.2007.03.018.
18. Kim JS, Chang JW, Yun HS, Yang KM, Hong EH, Kim DH, et al. Chloride intracellular channel 1 identified using proteomic analysis plays an important role in the radiosensitivity of HEp-2 cells via reactive oxygen species production. Proteomics 2010; 10:2589-604; PMID:20461716; http://dx.doi.org/10. 1002/pmic.200900523.
19. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91:325-34; PMID:9363941; http://dx.doi.org/10.1016/S0092-8674(00)80416-X.
20. Kang ES, Iwata K, Ikami K, Ham SA, Kim HJ, Chang KC, et al. Aldose reductase in keratinocytes attenuates cellular apoptosis and senescence induced by UV radiation. Free Radic Biol Med 2011; 50:680-8; PMID:21182935; http://dx.doi.org/10.1016/j.freeradbiomed.2010.12.021.
21. Suzuki K, Ojima M, Kodama S, Watanabe M. Radiation-induced DNA damage and delayed induced genomic instability. Oncogene 2003; 22:6988-93; PMID:14557802; http://dx.doi.org/10.1038/sj.onc.1206881.
22. Marín YE, Seiberg M, Lin CB. Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival. Exp Dermatol 2009; 18:611-8; PMID:19320734; http://dx.doi.org/10.1111/j.1600-0625. 2008.00839.x.
23. Wang C, Yan R, Luo D, Watabe K, Liao DF, Cao D. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 2009; 284:26742-8; PMID:19643728; http://dx.doi.org/10.1074/jbc.M109.022897.
24. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6:813-23; PMID:16990858; http://dx.doi.org/10.1038/nrc1951.
25. Westbury CB, Sahlberg KK, Borresen-Dale AL, Isacke CM, Yarnold JR. Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients. Radiat Oncol 2011; 6:42; PMID:21521514; http://dx.doi.org/10.1186/1748-717X-6-42.
26. Tammali R, Srivastava SK, Ramana KV. Targeting aldose reductase for the treatment of cancer. Curr Cancer Drug Targets 2011; 11:560-71; PMID:21486217.
27. 1-S phase transition through the AKT/phosphoinositide-3-kinase/E2F-1 pathway in human colon cancer cells. Mol Cancer Ther 2010; 9:813-24; PMID:20354121; http://dx.doi.org/10.1158/1535-7163. MCT-09-0795.
28. Selga E, Noé V, Ciudad CJ. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem Pharmacol 2008; 75:414-26; PMID:17945194; http://dx.doi.org/10.1016/j.bcp.2007.08.034.
29. Feinendegen LE. Reactive oxygen species in cell responses to toxic agents. Hum Exp Toxicol 2002; 21:85-90; PMID:12102502; http://dx.doi.org/10. 1191/0960327102 ht216oa.
30. Singh S, Sreenath K, Pavithra L, Roy S, Chattopadhyay S. SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme activity. Int J Biochem Cell Biol 2010; 42:1105-14; PMID:20097305; http://dx.doi.org/10.1016/j.biocel. 2010.01.022.
31. Liu J, Wen G, Cao D. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives. Recent Pat Anticancer Drug Discov 2009; 4:246-53; PMID:19522700; http://dx.doi.org/10.2174/157489209789206931.
32. El-Kabbani O, Old SE, Ginell SL, Carper DA. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. Mol Vis 1999; 5:20; PMID:10493777.
33. Kim JS, Park ZY, Yoo YJ, Yu SS, Chun JS. p38 kinase mediates nitric oxide-induced apoptosis of chondrocytes through the inhibition of protein kinase Czeta by blocking autophosphorylation. Cell Death Differ 2005; 12:201-12; PMID:15665819; http://dx.doi.org/10.1038/sj.cdd.4401511.